SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
Declared interim dividend of Rs. 7/- (Rupees Seven Only) per equity share of Re. l/- each of the Company for the financial year ending on March 31, 2022. Refer letter attached
Sun Pharma-arm Taro logs better-than-expected Q3 Ebitda margin; stock up 4%
In Q3FY22, Taro's EBITDA margins improved 108 bps year-on-year (YoY) to 31.3 per cent mainly due to better gross margins. Sun Pharma launches dry eye treatment product in Canada
New Delhi, Jan 27 Sun Pharmaceutical Industries on Thursday said its subsidiary has launched Cequa, a new treatment for dry eye disease, in Canada. .. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to the launch of PrCEQUA(tm), the first dry eye treatment with nanomicellar technology in Canada. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board to consider Dividend
This is to inform you that the Board of Directors of the Company, at its meeting scheduled to be held on Monday, January 31, 2022, will inter-alia consider declaration of Interim Dividend on the equity shares of the Company, for the financial year 2021-22. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 21, 2022 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation of loss of share certificate SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended December 31, 2021
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Ashok BhutaDesignation :- Any Other